Tejaswini Kulkarni
@tkulkarn1
Followers
800
Following
4K
Media
68
Statuses
889
#PulmCC Physician Scientist @uabmedicine| Director @ UAB-ILD program #curePF|@HarvardChanSPH alum|Wife and Triplet Mom #womeninmedicine| Tweets are mine.
Birmingham, AL
Joined November 2015
RT @CrisprSam: This is a wonderful recognition for CRISPR! Congrats to all the innovators for all these groundbreaking inventions.
0
4
0
RT @accpchest: #CHEST2024 Recap: Experts discussed how to evaluate and manage clinical worsening in patients with PH-ILD. Read more in CHE….
0
3
0
Our @AnnalsATS paper exploring factors associated with persistence of antifibrotic therapies among patients with IPF enrolled in @PFFORG registry is now in press; underscores the importance of addressing mental health. #curePF @ahajaricase @UABPulmonary
1
9
32
RT @KaminskiMed: Great talk at #ICLAF2024 by Prof Kulkarni.on phase 3 clinical trials in Pulmonary Fibrosis - provides insight on failure….
0
1
0
Excellent panel discussing disparities and environmental exposures in ILDs - #ICLAF2024 #CurePF
0
6
32
#ICLAF2024 kicking off with patient experience session and looking forward to 5 days of advances towards #curePF
0
0
25
RT @clautejera: Excellent discussion on early initiation of anti-fibrotic therapy in Non-IPF fibrotic lung disease, led by @tkulkarn1 and D….
0
4
0
RT @ATSCPAssembly: Join us for journal club Thursday, October 3rd, 10 am EST on "Microscopic Small Airway Abnormalities Identified in Early….
0
4
0
RT @KaminskiMed: Wow! Boehringer-Ingelheim announces that Nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study -….
0
32
0
RT @ThoraxBMJ: To commemorate Pulmonary Fibrosis Awareness Month, we will be sharing brilliant Pulmonary Fibrosis research from Thorax over….
0
10
0
In clinical practice,there are often questions about approach to positive antibodies in the absence clinical signs of SARD. This study shows that IPF disease course and response to Pirfenidone did not differ by autoantibody status #CurePF @cnewto.
Dr. Tejaswini Kulkarni (@tkulkarn1) and researchers at @UABPulmonary evaluated the association of antinuclear #antibodies, #rheumatoid factor, and 💊 treatment outcomes of patients with #IPF from the 🩺 Phase III ASCEND trial. @Pulmonary_Ther |
4
2
28
RT @DavidZhangMD: Telomere length testing is a readily available clinical test for precision management of ILD. We describe the clinical im….
0
22
0
A great discussion on the methodology of these upcoming guidelines and key take away points on management of patients with SARD-ILD - #curePF #CHEST_ILDTx @accpchest @ATSCPAssembly @PFFORG.
A Review of ACR/CHEST Clinical Practice Guidelines on Treatment of ILD With Systemic Autoimmune Rheumatic Diseases. Watch the full webinar by the Diffuse Lung Disease and Lung Transplant Network: #MedEd #MedTwitter #CHEST_ILDTx
0
2
19
RT @drdayjee: Prof. Athol Wells presents elegant data from a recent multinational Delphi consensus that:. • Progression of ILD is progressi….
0
10
0
RT @leticiakawano: Now please meet SUPER #ValerieQuinn, @REMAP_ILD project manager 🤩. Valerie rocks BIG TIME, you have no idea! Thanks, Val….
0
3
0
RT @drdayjee: …and a whole lot of good cheer with friends from all around the globe 🌏!!!. #LearningFromTheBest.#ATS2024 .#MTWC
https://t.co….
0
4
0
Excellent discussions on the potential applications of AI-driven tools in management of patients with PF- much more to be done to change the landscape to meet criteria for meaningful endpoint! #curePF
💡Poster Discussion Session: 🤖 Machine learned: AI-driven solutions in #ILD and 🫁 transplant!.Where: Room 33A-C.🕰️ 9:15 AM. Moderators: @tkulkarn1 , @SteveMHumphries & @andreaohMD . #ATS2024 . @atscommunity @ATS_Assemblies
0
3
13